Sugi Predict

Sugi Predict / Compounds / SCHEMBL4085620

SCHEMBL4085620

SCHEMBL4085620

CCCCc1ccc(C(NC(=O)Nc2cccc(S(C)(=O)=O)c2)c2ccc(C(=O)Nc3nn[nH]n3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYSLTR2 Q9NS75 7/20 0.42
▸ CYSLTR1 Q9Y271 7/20 0.42
▸ TRPV1 Q8NER1 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ GCGR P47871 3/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ GALR3 O60755 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PLK1 P53350 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ ADCY6 O43306 1/20 0.38
▸ ADCY3 O60266 1/20 0.38
▸ ADCY9 O60503 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081625 0.89 ALDH1A1 (0.43) GCGRMEN1ALDH1A1KMT2ANPC1
SCHEMBL4081375 0.88 TRPV1 (0.55) CYSLTR2CYSLTR1TRPV1GCGRADCY6
SCHEMBL4091978 0.86 GCGR (0.51) GCGRMEN1ALDH1A1KMT2ANPC1
SCHEMBL4086797 0.86 CYSLTR2 (0.42) CYSLTR2CYSLTR1TRPV1MEN1ALDH1A1
SCHEMBL4091869 0.85 ABCG2 (0.46) CYSLTR2CYSLTR1TRPV1MEN1ALDH1A1
SCHEMBL4091306 0.82 MGAT2 (0.42) GCGRMEN1ALDH1A1KMT2ACA12
SCHEMBL4085611 0.82 KDM4E (0.43) CYSLTR2CYSLTR1TRPV1KDM4EGCGR
SCHEMBL4085175 0.82 GCGR (0.43) GCGRMEN1ALDH1A1KMT2ALMNA
SCHEMBL4092088 0.82 GCGR (0.47) GCGRMEN1ALDH1A1KMT2ANPC1
SCHEMBL4092624 0.79 GCGR (0.53) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CYSLTR2 2665/4885CYSLTR1 2292/4885TRPV1 1930/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR CYSLTR2 2665/4885CYSLTR1 2292/4885TRPV1 1930/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CYSLTR2 2665/4885CYSLTR1 2292/4885TRPV1 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.